

a). Amendment to the Claims

Claims 1-15 (Cancelled)

16. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an indolocarbazole derivative, said pharmaceutically acceptable carrier and said indolocarbazole derivative being encapsulated in a liposome with an average particle size of 120 to 500 nm, said liposome consisting of lipid(s) selected from the group consisting of (i) hydrogenated soybean phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid distearoyl phosphoethanolamine (PEG-DSPE).

Claims 17-18 (Cancelled).

19. (Currently Amended) The pharmaceutical composition according to claim 16, wherein the lipids are mixed lipids of hydrogenated soybean phosphatidylcholine and ~~polyethylene glycol-modified phospholipid~~ PEG-DSPE.

20. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the lipids are hydrogenated soybean phosphatidylcholine.

Claims 21-34 (Cancelled).

35. (Currently Amended) The pharmaceutical composition according to any one of claims ~~46, 49 or 20~~ 16, 19, 20 or 49, wherein said liposome comprises at least two bilayers of said lipid(s).

Claims 36-41 (Cancelled)

42. (Currently Amended) A liposome preparation, comprising liposomes encapsulating an indolocarbazole derivative, said liposomes having an average particle size of 120 nm to 500 nm, wherein the liposomes consist of lipid(s) selected from the group consisting of (i) hydrogenated soybean phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified ~~phospholipid distearoyl phosphoethanolamine~~ PEG-DSPE.

43. (Currently Amended) The liposome preparation according to claim 42, wherein the lipids are mixed hydrogenated soybean phosphatidylcholine and ~~polyethylene glycol-modified phospholipid~~ PEG-DSPE.

44. (Previously Presented) The liposome preparation according to claim 42, wherein the lipid is hydrogenated soybean phosphatidylcholine.

Claims 45-48 (Cancelled).

49. (New) The pharmaceutical composition according to claim 16, wherein the average particle size of the liposomes is 130 to 186 nm.

50. (New) The liposome preparation according to claim 42, wherein the average particle size of the liposomes is 130 to 186 nm.